Physician profile
Meghan Lambert
NPI 1588819361
$4,984.33
in general payments reported to CMS, 2019-2025
21 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.23 · 2020: $128 · 2021: $510 · 2022: $982 · 2023: $1,268 · 2024: $1,013 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,941 · Entertainment: $393 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,940.67 |
| Entertainment | $393.47 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,262.17 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Coopervision INC. | $670.74 | 2020-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $647.92 | 2019-2025 | Precision 1, Total30, Rhopressa |
| Optos, INC. | $523.23 | 2022-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Sun Pharmaceutical Industries INC. | $347.79 | 2022-2025 | Bromsite, Xelpros, Cequa |
| Tarsus Pharmaceuticals, INC. | $336.10 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $185.46 | 2022-2023 | Tearcare System |
| Kala Pharmaceuticals, INC. | $160.67 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $156.97 | 2020-2021 | |
| Allergan, INC. | $148.27 | 2020-2022 | |
| Glaukos Corporation | $110.01 | 2022 | |
| Oyster Point Pharma, INC. | $103.25 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $61.29 | 2025 | Oxervate |
| Abbvie INC. | $52.75 | 2023 | |
| Harrow Eye, LLC | $49.92 | 2024-2025 | Vevye |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $46.08 | 2020 | |
| Glaxosmithkline, LLC. | $41.97 | 2022-2023 | Benlysta |
| Thea Pharma INC. | $33.64 | 2022-2023 | |
| Biotissue Holdings INC. | $23.25 | 2023 | |
| Novartis Pharmaceuticals Corporation | $22.85 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.